Single Nucleotide Polymorphism Clustering in Systemic Autoimmune Diseases
نویسندگان
چکیده
منابع مشابه
Single Nucleotide Polymorphism Clustering in Systemic Autoimmune Diseases
Systemic Autoimmune Diseases, a group of chronic inflammatory conditions, have variable symptoms and difficult diagnosis. In order to reclassify them based on genetic markers rather than clinical criteria, we performed clustering of Single Nucleotide Polymorphisms. However naive approaches tend to group patients primarily by their geographic origin. To reduce this "ancestry signal", we develope...
متن کاملSingle Nucleotide Polymorphism Analysis of Protamine Genes in Infertile Men
Background Single nucleotide polymorphism (SNPs) are considered as one of the underlying causes of male infertility. Proper sperm chromatin packaging which involves replacement of histones with protamines has profound effect on male fertility. Over 20 SNPs have been reported for the protamine 1 and 2. MaterialsAndMethods The aim of this study was to evaluate the frequency of two previously repo...
متن کاملSystemic Autoimmune Diseases 2014
1Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China 2Laboratory of Autoimmunity, School of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA 3Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7660, USA 4Department of Rheumatology, Peking Un...
متن کاملSystemic Autoimmune Diseases
1 Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China 2Department of Biological Sciences, University of Texas at El Paso, 500 West University Avenue, El Paso, TX 79968, USA 3Microbiology, College of Medicine University of Nebraska Medical Center, Omaha, NE 68198-7660, USA 4Department of Rheumatology, Peking Union Medical College Hosp...
متن کاملBiomarkers in Systemic Autoimmune Diseases
In an ideal scenario, a biomarker would both reveal the driver of disease and identify an effective treatment. In oncology, genetic biomarkers that molecularly or clinically classify patient populations for targeted therapies, e.g., BRAF [1] and HER-2 [2], have been clinically validated and are reaching this ideal. However, biomarkers are necessarily based on the pathobiology of the underlying ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS ONE
سال: 2016
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0160270